Results 1 to 10 of about 28,144 (206)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Clinical Pharmacology: Advances and Applications, 2013
Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global ...
Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE   +7 more
doaj   +1 more source

Apixaban linearity profile for hydrotropic solubilization

BLDE University Journal of Health Sciences, 2020
A study on the hydrotropic solubility and linearity profile of Apixaban was carried out by using Sodium Salicylate as the solubilizing agent as Apixaban is poorly soluble in water.
Santosh Karajgi, Shripad Potadar
doaj   +1 more source

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

Journal of Comparative Effectiveness Research, 2023
Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or ...
Josep Comin Colet, Antoni Sicras Mainar, Joel Salazar-Mendiguchia, Isabel del Campo Alonso, Ainara Echeto, David Vilanova Larena, Olga Delgado Sanchez   +6 more
doaj   +1 more source

Development of Pacemaker Lead Thrombosis in a Patient with Atrial Fibrillation during Apixaban Treatment

Journal of Tehran University Heart Center, 2019
Apixaban was introduced in clinical use for nonvalvular atrial fibrillation as an alternative to warfarin. There is a dearth of information regarding apixaban use in patients suffering from atrial fibrillation with intracardiac foreign bodies such as ...
Adem Adar, Orhan Önalan, Fahri Cakan
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source

Accidental apixaban intoxication in a 23-month-old child: a case report

BMC Pediatrics, 2020
Background Direct oral anticoagulants, such as apixaban, are increasingly used in everyday practice in order to treat or prevent thromboembolic diseases. To date, there is no available data about apixaban pharmacokinetics in children, and no intoxication
Manon Launay, Yara Nasser, Isabelle Maubert, Anne-Cécile Chaux, Xavier Delavenne   +4 more
doaj   +1 more source

Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial Substudy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The SAXOPHONE (Safety of Apixaban on Pediatric Heart Disease on the Prevention of Embolism) trial demonstrated the safety of apixaban for thromboprophylaxis in children with heart disease.
Ghada A. Aborkhees, Amy J. Barr, Kevin Dietrich, Christoph Male, Zhaoqing Wang, Chen Yao, R. Mark Payne, Andrew C. Glatz, Paul Monagle, Kristin M. Burns, Alison M. Reedy, Joshua L. Dyme, Peter H. Schafer, Antoinette Ajavon‐Hartmann, Lesley G. Mitchell   +14 more
doaj   +1 more source

Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.

PLoS ONE, 2013
Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings.
Gines Escolar, Victor Fernandez-Gallego, Eduardo Arellano-Rodrigo, Jaume Roquer, Joan Carles Reverter, Victoria Veronica Sanz, Patricia Molina, Irene Lopez-Vilchez, Maribel Diaz-Ricart, Ana Maria Galan   +9 more
doaj   +1 more source

Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting

Journal of Comparative Effectiveness Research
Aim: Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) formedical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF.
Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk   +9 more
doaj   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj